8-K: BIO-key International Faces Nasdaq Delisting Notice and Restatement of Financials

BIO-key International received a non-compliance notice from Nasdaq for failing to file its annual report on time and will restate previous financial statements due to accounting errors.

Summary

• BIO-key International received a notice from Nasdaq for not filing its 2023 annual report on time.
• The company has 60 days to submit a plan to regain compliance, with a potential extension to October 14, 2024.
• The company will restate its financial statements for the first three quarters of 2023 due to revenue recognition errors at its European subsidiary.
• The restatement will also address understated allowances for accounts receivable and inventory reserves.
• The company's previously issued financial statements for the affected periods should no longer be relied upon.
• The company is working with its audit committee to determine the full impact of the adjustments.
• The company intends to file its 2023 annual report and amended quarterly reports as soon as practicable.

Sentiment

Score: 2

Explanation: The document indicates significant issues with financial reporting and compliance, leading to a negative sentiment. The risk of delisting and the need for restatements are major concerns.

Positives

• The company intends to file the 2023 annual report and amended quarterly reports as soon as practicable.
• The company is working with its audit committee to determine the full impact of the adjustments.

Negatives

• The company received a non-compliance notice from Nasdaq.
• The company failed to file its 2023 annual report on time.
• The company will restate its financial statements for the first three quarters of 2023.
• Revenue recognition errors were made at the European subsidiary.
• Allowances for accounts receivable and inventory reserves were understated.
• Previously issued financial statements for the affected periods should not be relied upon.

Risks

• There is a risk of delisting from Nasdaq if the company fails to regain compliance.
• The restatement of financial statements could negatively impact investor confidence.
• The company may face further adjustments to its financial statements.
• The company's internal control over financial reporting and disclosure controls and procedures are being assessed.
• The company has a history of losses and limited revenue, which could impact its ability to raise additional capital.

Future Outlook

The company intends to file its 2023 annual report and amended quarterly reports as soon as practicable and regain compliance with Nasdaq listing requirements.

Management Comments

• Management is assessing the effect of these restatements on the company's internal control over financial reporting and its disclosure controls and procedures.
• The company intends to file its Annual Report on Form 10-K for the year ended December 31, 2023, containing audited financial statements prepared in accordance with U.S. GAAP that will reflect correction of the foregoing errors as soon as practicable.

Industry Context

The issues at BIO-key highlight the importance of robust internal controls and accurate financial reporting, which are critical for maintaining investor confidence in the technology sector.

Comparison to Industry Standards

• Many technology companies, especially those with international operations, face challenges in revenue recognition and financial reporting.
• Companies like Okta and Ping Identity, which also operate in the identity and access management space, have faced similar challenges in the past, highlighting the complexity of this sector.
• The restatement of financials and the potential delisting notice are significant deviations from industry best practices, which emphasize timely and accurate financial reporting.

Stakeholder Impact

• Shareholders may experience a decline in share value due to the non-compliance notice and financial restatement.
• Employees may be concerned about the company's financial stability and future prospects.
• Customers and suppliers may have concerns about the company's ability to operate effectively.

Next Steps

• The company needs to submit a plan to Nasdaq to regain compliance within 60 days.
• The company will file its 2023 annual report and amended quarterly reports as soon as practicable.
• The company will complete its review of the financial statements and determine the full impact of the adjustments.

Key Dates

Keywords

Nasdaq, delisting, non-compliance, financial restatement, revenue recognition, accounting errors, Form 10-K, Form 10-Q, BIO-key, Swivel Secure Europe